Group 1 - A class action has been filed on behalf of investors who acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025, and May 26, 2025 [1] - The allegations state that Rocket Pharmaceuticals misled investors regarding the viability and efficacy of its RP-A501 drug, particularly concerning the Phase 2 pivotal trial for Danon disease [2] - Following the announcement of a Serious Adverse Event (SAE) related to the trial, Rocket's stock price dropped significantly from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025 [3] Group 2 - The complaint highlights that the company created a false impression of having reliable information about the trial's timeline and safety, which was contradicted by the reality of the situation [2] - The FDA placed the trial on hold due to the introduction of a novel immunomodulatory agent, which was part of an amended protocol that led to a patient's death [2] - Shareholders interested in participating in the class action can contact Robbins LLP, with the option to serve as lead plaintiff or remain an absent class member [4]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025, and May 26, 2025, due to allegations of misleading information regarding the company's clinical trial for RP-A501 [1][2]. Group 1: Allegations and Company Actions - The lawsuit claims that Rocket Pharmaceuticals misrepresented the viability and efficacy of RP-A501, particularly regarding the timeline and safety of its Phase 2 pivotal trial for Danon disease [2]. - It is alleged that the company provided an overly optimistic outlook on the trial's progress, which was contradicted by the reality of a Serious Adverse Event (SAE) that resulted in a patient's death after protocol amendments were made [2]. - Following the announcement of the SAE on May 27, 2025, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share [3]. Group 2: Class Action Participation - Shareholders interested in participating in the class action can contact Robbins LLP to serve as lead plaintiff, representing other class members in the litigation [4]. - Shareholders are not required to take action to be eligible for recovery and can remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP has been a leader in shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5].